Dogwood Therapeutics, Inc.

DWTX
$1.81 (- $0.03 - 1.63%)
Last updated: 2026-05-22 12:49 UTC
DWTX Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS92829J1043
CUSIP92829J104
Market Price1.81
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-25.59
Market Cap$122.9M
Book Value-14.42
Price to Book-0.287
Beta1.88
52w High29.28
52w Low1.87
Next Earnings DateN/A

Dogwood Therapeutics, Inc. trades under ticker DWTX on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US92829J1043, CUSIP 92829J104.

About the Company
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and IMC-2, a combination of valacyclovir and celecoxib in Phase 2 clinical trial for the treatment of long-COVID and post-acute sequelae of COVID-19 infection. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2012 and is based in Alpharetta, Georgia.
Price History